Gilead pays $43M to license Xilio’s IL-12 program that could turn ‘cold’ tumors ‘hot’
Xilio Therapeutics had a bevy of announcements on Thursday — it entered a licensing deal for its Phase 1 IL-12 program with …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
